01—Abstract
Summary
Summary of the 8-K/A filed December 17, 2025. Cited figures are marked; the original filing is the authoritative source.
Axon Enterprise, Inc. (AXON) has filed an 8-K report detailing the closing of privately negotiated exchange transactions involving its 0.50%a Convertible Senior Notes due 2027.
These transactions allowed certain holders to exchange a significant principal amount of Notes for a combination of cash and Axon's common stock. This exchange effectively reduces the company's outstanding convertible debt and increases its outstanding share count, which are key considerations for investors assessing the company's capital structure and potential dilution.
02—Key points
Key Highlights
- Closed privately negotiated exchange transactions for 0.50% Convertible Senior Notes due 2027 on December 16, 2025.
- Exchanged $196,854,000 in aggregate principal amount of Notes.
- Consideration for the exchange included $196,859,243.77 in cash (including accrued interest and cash for fractional shares).
- An additional 526,802 shares of Axon's common stock were issued as part of the exchange consideration.
- An additional $19,000,000 aggregate principal amount of Notes were exchanged in a separate agreement entered into on December 15, 2025, subsequent to a prior 8-K filing.
- These transactions are classified as unregistered sales of equity securities.
03—Questions
Frequently Asked Questions
What was the primary purpose of these exchange transactions?
The primary purpose was for certain holders of Axon's 0.50% Convertible Senior Notes due 2027 to exchange their Notes for a mix of cash and Axon common stock, thereby reducing the company's outstanding convertible debt.
How does this impact Axon's outstanding shares?
The issuance of 526,802 shares of common stock as part of the exchange consideration will increase the total number of outstanding shares, which could lead to a dilutive effect for existing shareholders.
What is the total value of the Notes exchanged and the consideration provided?
A total of $196,854,000 in aggregate principal amount of Notes were exchanged. The consideration provided by Axon consisted of $196,859,243.77 in cash and 526,802 shares of common stock.
Were these shares sold through a public offering?
No, these were privately negotiated exchange transactions, and the shares issued are considered unregistered sales of equity securities.
04—Continue